Addex Therapeutics’ neuropsychiatric-focused spinout has raised $105 million in series B funds to bankroll a planned phase 2 study of its schizophrenia treatment.
While Kyverna awaits an FDA decision on whether to grant the first-ever approval for an autoimmune CAR-T therapy, the biotech ...
Charles River Laboratories has acquired two of Tigermed’s Frontage laboratory sites in Pennsylvania for $470 million upfront ...
The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post ...
Boehringer Ingelheim is gearing up to take survodutide to regulators next year after the obesity drug proved its ...
Vor Bio is paying RemeGen $10 million upfront in cash and issuing warrants valued at approximately $46 million for rights to RC298 outside Greater China, adding a long-acting drug ...
Argenx has struck a deal to acquire Unnatural Products (UNP) for $550 million upfront, snapping up the Merck & Co.- and ...
Mirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late ...
The U.S. Treasury's COINS Act proposal aims to shield U.S. biotech from Chinese competition, but insiders warn it will ...
PepGen’s phase 2 myotonic dystrophy type 1 (DM1) data have met analysts’ best-case scenario, causing the biotech’s share ...
Generate Biomedicines' CEO has hailed the “huge opportunity” offered by AI tools after the Flagship-founded company used ...
Zura Bio’s tibulizumab has flunked a phase 2 hidradenitis suppurativa (HS) trial, prompting the biotech to end development in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results